Explain the pathophysiology of the plasma cell disorder AL amyloidosis to enhance understanding of disease mechanisms. |
|
|
|
|
|
Analyze recent data on therapeutic advances and evolving practice standards in AL amyloidosis and integrate this information into the selection of optimal systemic therapies for patients. |
|
|
|
|
|
Implement strategies to enhance patient-centered care. |
|
|
|
|
|
Evaluate the design and eligibility criteria of ongoing clinical trials for AL amyloidosis and facilitate appropriate patient enrollment or referral. |
|
|
|
|
|